경증 천식의 관리: 흡입스테로이드의 지속적 투여에 대한 논란
Treatment of mild asthma: Is it necessary to keep regular inhaled corticosteroids?
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The main goal of asthma treatment is an adequate control of symptoms and a reduction in future exacerbations. To achieve the goal, international guidelines recommend daily use of controllers, such as inhaled corticosteroids (ICSs), even in patients with mild asthma. However, poor adherence is an unavoidable issue in the management of mild asthma. In addition, there is concern about possible adverse reactions and economic burden by unnecessary treatment. Recently, several studies have shown that as-needed use of ICSs has similar effects as regular use of ICSs on the prevention of acute asthmatic exacerbations. However, daily regular use of ICSs seems to be superior in terms of symptom-free days or airway inflammation suppression. Further studies are needed to determine whether symptom-driven use of ICSs can be an effective strategy for the management of mild asthma. Also, it is necessary to develop proper methods that can predict mild asthmatics who experience frequent exacerbations if they stop regular ICSs.
Abstract
The main goal of asthma treatment is an adequate control of symptoms and a reduction in future exacerbations. To achieve the goal, international guidelines recommend daily use of controllers, such as inhaled corticosteroids (ICSs), even in patients with mild asthma. However, poor adherence is an unavoidable issue in the management of mild asthma. In addition, there is concern about possible adverse reactions and economic burden by unnecessary treatment. Recently, several studies have shown that as-needed use of ICSs has similar effects as regular use of ICSs on the prevention of acute asthmatic exacerbations. However, daily regular use of ICSs seems to be superior in terms of symptom-free days or airway inflammation suppression. Further studies are needed to determine whether symptom-driven use of ICSs can be an effective strategy for the management of mild asthma. Also, it is necessary to develop proper methods that can predict mild asthmatics who experience frequent exacerbations if they stop regular ICSs.
참고문헌 (23)
- 윤호주, "Intermittent to Mild Asthma: The Need for Continued Treatment", Allergy, Asthma & Immunology Research, 5(6), pp.341~342 (2013), 대한천식알레르기학회
- Adams NP, "Inhaled beclomethasone versus placebo for chronic asthma", Cochrane Database Syst Rev, 1, pp.CD002738~ (2005)
- "GINA Report, Global strategy for asthma management and prevention" (2014)[URL]
- Boushey HA, "Daily versus as-needed corticosteroids for mild persistent asthma", N Engl J Med, 352, pp.1519~1528 (2005)
- Papi A, "Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma", N Engl J Med, 356, pp.2040~2052 (2007)
- Rodrigo GJ, "intermittent inhaled corticosteroids for recurrent wheezing and mild persistent asthma: a systematic review with meta-analysis", Respir Med, 107, pp.1133~1140 (2013)
- Dusser D, "Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations", Allergy, 62, pp.591~604 (2007)
- Vignola AM, "Airway inflammation in mild intermittent and in persistent asthma", Am J Respir Crit Care Med, 157, pp.403~409 (1998)
- Boulay ME, "Discordance between asthma control clinical, physiological and inflammatory parameters in mild asthma", Respir Med, 107, pp.511~518 (2013)
- Mitchell, "Near-fatal asthma: a population-based study of risk factors", Chest, 121, pp.1407~1413 (2002)
- O'Byrne PM, "Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial", Am J Respir Crit Care Med, 164(8 Pt 1), pp.1392~1397 (2001)
- Pauwels RA, "Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial", Lancet, 361, pp.1071~1076 (2003)
- Viswanathan M, "Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review", Ann Intern Med, 157, pp.785~795 (2012)
- Beasley R, "Combination corticosteroid", β-agonist inhaler as reliever therapy: a solution for intermittent and mild asthma?, 2014, pp.133, 39~41
- Patel M, "Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial", Lancet Respir Med, 1, pp.32~42 (2013)
- Papi A, "Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial", Lancet Respir Med, 1, pp.23~31 (2013)
- Tamaoki J, "Role of regular treatment with inhaled corticosteroid or leukotriene receptor antagonist in mild intermittent asthma", Allergy Asthma Proc, 29, pp.189~196 (2008)
- Haahtela T, "Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma", N Engl J Med, 331, pp.700~705 (1994)
- Green RH, "Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial", Lancet, 360, pp.1715~1721 (2002)
- Smith AD, "Use of exhaled nitric oxide measurements to guide treatment in chronic asthma", N Engl J Med, 352, pp.2163~2173 (2005)
- Deykin A, "Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids", J Allergy Clin Immunol, 115, pp.720~727 (2005)
- Lim KG, "The use of fraction of exhaled nitric oxide in pulmonary practice", Chest, 133, pp.1232~1242 (2008)
- Calhoun WJ, "Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial", JAMA, 308, pp.987~997 (2012)